EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of Inflammatory Markers as Prognostic Factors in the Treatment of Hepatocellular Carcinoma (HCC) with Degradable Starch Microspheres by Transarterial Chemoembolization (DSM-TACE)

Hannah L Steinberg-Vorhoff, Andriana Tropotel, Jens M Theysohn iD, Benedikt Schaarschmidt iD, Johannes Haubold iD, Matthias Jeschke, Leonie Jochheim, Johannes M Ludwig iD

Cancers · 14.02.2025 · 17 (4) · 647

DOI: 10.3390/cancers17040647 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 14.02.2025. Verfasst von Hannah L Steinberg-Vorhoff und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 4…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the prognostic value of pre-therapeutic inflammatory markers before transarterial chemoembolization with degradable starch microspheres (DSM-TACE) in the treatment of hepatocellular carcinoma (HCC).

Methods

A total of 155 patients (81% male, median age: 68 years) who underwent first-time DSM-TACE between 07/13 and 06/22 were included in the study. Inflammatory indices were dichotomized using median values. Cox proportional hazard model for univariate (UVA) and multivariate (MVA) analyses (hazard ratio; 95% CI, p-value) and Kaplan–Meier analyses (overall survival (OS) in months; 95% CI; log-rank test) were performed.

Results

The median OS of the study cohort was 15.9 (12.9–20) months with a median survival according to BCLC stages A (12%), B (41%), and C (47%) of median not reached, 19.3 (15.3–27), and 7.2 (4.5–9.0) months, respectively (p < 0.0001). In the UVA, several inflammatory markers on OS were statistically significant with the systemic inflammatory response index (SIRI; ≤median (2.04) HR: 0.41 (0.19–0.89); p = 0.024) and the lymphocyte to monocyte ratio (LMR; >median (1.82) HR: 0.44 (0.2–0.9); p = 0.025) remaining statistically significant in MVA together with the BCLC stage (p = 0.0001), ALBI grade (p = 0.016), hepatic tumor burden (≤25% vs. >25%; p = 0.006), and largest HCC lesion (≤5.5 cm vs. >5.5 cm; p = 0.008). In subgroup analysis, patients with elevated LMR and reduced SIRI exhibited significantly prolonged overall survival (OS) in both BCLC B (p < 0.0001) and Child–Pugh A (p = 0.021) subgroups.

Conclusion

The findings suggest that SIRI and LMR may serve as valuable tools in identifying BCLC B and Child–Pugh A patients who could potentially benefit better from DSM-TACE treatment. Nevertheless, further research is recommended to confirm these findings and to provide more comprehensive insights.

Schlagwörter

Stichwörter der Autor:innen

bridging to transplantationcarcinomachemoembolizationdegradable starch microsphere (DSM) TACEhepatocellularinflammatory markerstherapeutic

Autor:innen und Institutionen

  • Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany.
  • Institute of Diagnostic Radiology, Interventional Radiology and Nuclear Medicine, BG Clinics Bergmannsheil, Ruhr-University of Bochum, Buerkle-de-la-Camp Platz 1, 44789 Bochum, Germany.
  • Department of Gastroenterology and Hepatology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany.
  • Department of Radiology and Nuclear Medicine, University Medical Center Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany.

ORCID-Profile: Jens M Theysohn, Benedikt Schaarschmidt, Johannes Haubold, Johannes M Ludwig

Zitieren

APA

Steinberg-Vorhoff, H. L., Tropotel, A., Theysohn, J. M., Schaarschmidt, B., Haubold, J., Jeschke, M., Jochheim, L., & Ludwig, J. M. (2025). Evaluation of Inflammatory Markers as Prognostic Factors in the Treatment of Hepatocellular Carcinoma (HCC) with Degradable Starch Microspheres by Transarterial Chemoembolization (DSM-TACE). Cancers, 17(4), 647. https://doi.org/10.3390/cancers17040647

Vancouver

Steinberg-Vorhoff HL, Tropotel A, Theysohn JM, Schaarschmidt B, Haubold J, Jeschke M, et al. Evaluation of Inflammatory Markers as Prognostic Factors in the Treatment of Hepatocellular Carcinoma (HCC) with Degradable Starch Microspheres by Transarterial Chemoembolization (DSM-TACE). Cancers. 2025;17(4):647. doi:10.3390/cancers17040647

BibTeX
@article{SteinbergVorhoff2025,
  author = {Steinberg-Vorhoff, Hannah L and Tropotel, Andriana and Theysohn, Jens M and Schaarschmidt, Benedikt and Haubold, Johannes and Jeschke, Matthias and Jochheim, Leonie and Ludwig, Johannes M},
  title = {Evaluation of Inflammatory Markers as Prognostic Factors in the Treatment of Hepatocellular Carcinoma (HCC) with Degradable Starch Microspheres by Transarterial Chemoembolization (DSM-TACE)},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {4},
  pages = {647},
  doi = {10.3390/cancers17040647}
}
Kostenlos starten →